Clinical Trial

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-06; most recent amendment 2025-09-08.
Trial Details
NCT Number NCT07021209
Lead Sponsor Grit Biotechnology
Collaborators: Tongji Hospital
Conditions Neurological Autoimmune Diseases
Enrollment 30 participants
Start Date 2025-01-14
Primary Completion 2028-01-13 (estimated)
Study Completion 2028-01-13 (estimated)
Updated on ClinicalTrials.gov 2025-09-15